Novartis has dropped a phase 2-stage radioligand therapy (RLT) after the candidate disappointed in the clinic. The Swiss pharma had been evaluating the gastrin-releasing peptide receptor ...

A phase 2 study of Agios Pharmaceuticals’ next-generation pyruvate kinase (PK) activator has failed to support continued ...

San Diego-based Axiom Biosciences intends to go public via a listing on the Hong Kong Stock Exchange (HKEX) followed by a ...

For years, as Big Pharma poured billions into antibody-drug conjugates, Novartis CEO Vas Narasimhan notably stayed on the ...

The nonprofit Center for Therapeutic Genetics (CTG) will have a small physical space at the Broad Institute of MIT and ...

India-based Lupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit ...

Jupiter Neurosciences will pay $3.3 million upfront to Canada's PharmAla Biotech for the U.S. rights to an MDMA drug to treat ...

Bristol Myers Squibb has touted its strengthened collaboration with Nvidia as aiming to build the “most powerful AI factory ...

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in ...

Scribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing. | Scribe Therapeutics has put its IPO plans down on ...

A phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...